Today, Bedrocan produces five plant varieties for patient use. Each product is standardised according to pharmaceutical standards with a defined active ingredient composition. This reproducible chemical profile allows doctors to monitor dosage and condition progress like they would with any other treatment.
At Bedrocan we consider scientific research a vital tool to make medicinal cannabis an approved medicine. That’s why we support clinical trials worldwide and offer our services and experience to medicinal cannabis research projects.
Bedrocan products are used by the pharmaceutical industry. Standardised Active Pharmaceutical Ingredients (API) of pharmaceutical quality, in various formats, meet the needs of large and small drug developers.
Bedrocan will be present at the 2020 Norwegian Pain Society conference (Oslo, January 9-10). Dr. Mikael Kowal will give a short presentation and present a poster on the LUMC clinical study that showed promising results with fibromyalgia patients.